← The Wire
LXEONasdaq
Lexeo Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · CIK 1907108
Develops gene therapies for genetic cardiovascular diseases using AAV vectors
red 8-K · 90d
$343M
Market cap
$4.81
Last close
+1.3%
1D
-4.6%
5D
1.0M
Volume
Price · last 39 sessions-17.1%
May 4L $4.13 · H $6.23Jun 29
70
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 29, 20268-KReg FD Disclosure · Company UpdateJun 15, 202610-Q10-QMay 11, 20268-KResults of Operations · Company UpdateMay 11, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 20268-KExecutive ChangeApr 30, 202610-K10-KMar 30, 20268-KResults of Operations · Company UpdateMar 30, 20268-KExecutive ChangeFeb 5, 20268-KExecutive ChangeJan 27, 20268-KReg FD Disclosure · Company UpdateJan 12, 202610-Q10-QNov 5, 20258-KResults of OperationsNov 5, 20258-KMaterial Agreement · Results of OperationsOct 17, 2025424B5424B5Oct 17, 2025424B5424B5Oct 16, 20258-KReg FD Disclosure · Company UpdateOct 7, 202510-Q10-QAug 14, 20258-KExecutive Change · Results of OperationsAug 14, 20258-KShareholder VoteJun 30, 2025DEFA14ADEFA14AJun 5, 20258-KMaterial Agreement · Equity IssuanceMay 27, 202510-Q/A10-Q/AMay 15, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 20258-KReg FD Disclosure · Company UpdateApr 7, 2025424B5424B5Mar 24, 202510-K10-KMar 24, 20258-KResults of OperationsMar 24, 20258-KCompany UpdateJan 13, 20258-KExecutive ChangeDec 19, 202410-Q10-QNov 13, 20248-KExecutive Change · Results of OperationsNov 13, 2024SC 13GLEXEO THERAPEUTICS, INC.Nov 12, 20248-KCompany UpdateOct 30, 20248-KCompany UpdateOct 9, 202410-Q10-QAug 12, 20248-KResults of OperationsAug 12, 20248-KCompany UpdateJul 15, 20248-KExecutive Change · Company UpdateJul 8, 20248-KShareholder VoteJun 28, 20248-KResults of OperationsMay 9, 202410-Q10-QMay 9, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 20248-KMaterial Agreement · Company UpdateApr 22, 20248-KExecutive ChangeApr 22, 20248-KCompany UpdateApr 16, 2024S-1S-1Apr 9, 20248-KMaterial Agreement · Results of OperationsMar 11, 202410-K10-KMar 11, 2024SC 13GSC 13GFeb 14, 2024SC 13GSC 13GFeb 14, 2024SC 13GLEXEO THERAPEUTICS, INC.Feb 14, 2024SC 13GSC 13GFeb 13, 20248-KReg FD DisclosureFeb 5, 20248-KReg FD DisclosureDec 18, 2023SC 13GSC 13GDec 11, 20238-KResults of OperationsDec 11, 202310-Q10-QDec 11, 2023SC 13GSC 13GNov 24, 2023SC 13GSC 13GNov 17, 20238-KBylaw AmendmentNov 7, 2023424B4424B4Nov 6, 2023S-1/AS-1/ANov 1, 2023S-1/AS-1/AOct 30, 2023S-1S-1Sep 29, 2023
Insider Activity
In the 90 days to Feb 18, 2026: 2 sold $84K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 18, 2026 | Townsend Richard NolanChief Executive Officer | Sell | 10,173 | $6.38 | $65K |
| Feb 18, 2026 | Otero Jose ManuelChief Operating Officer | Sell | 3,016 | $6.40 | $19K |
| Nov 18, 2025 | Townsend Richard NolanChief Executive Officer | Sell | 1,127 | $9.27 | $10K |
| Nov 18, 2025 | Otero Jose ManuelChief Operating Officer | Sell | 721 | $9.27 | $7K |
| Nov 18, 2025 | Adler EricChief Medical Officer | Sell | 615 | $9.27 | $6K |
| Nov 18, 2025 | Robertson JennyChief Legal Officer | Sell | 549 | $9.27 | $5K |
| Nov 18, 2025 | See Tai SandiChief Development Officer | Sell | 386 | $9.27 | $4K |
| Oct 17, 2025 | Townsend Richard NolanChief Executive Officer | Sell | 12,985 | $8.94 | $116K |
| Oct 17, 2025 | See Tai SandiChief Development Officer | Sell | 3,844 | $8.94 | $34K |
| Oct 17, 2025 | Robertson JennyChief Legal Officer | Sell | 3,486 | $8.94 | $31K |
| Oct 17, 2025 | Adler EricChief Medical Officer | Sell | 3,344 | $8.94 | $30K |
| Oct 17, 2025 | Otero Jose ManuelChief Technical Officer | Sell | 2,091 | $8.94 | $19K |
| Oct 17, 2025 | Townsend Richard NolanChief Executive Officer | Sell | 148 | $9.56 | $1K |
| Oct 17, 2025 | See Tai SandiChief Development Officer | Sell | 44 | $9.56 | $421 |
| Oct 17, 2025 | Robertson JennyChief Legal Officer | Sell | 40 | $9.56 | $382 |
| Oct 17, 2025 | Adler EricChief Medical Officer | Sell | 38 | $9.56 | $363 |
| Oct 17, 2025 | Otero Jose ManuelChief Technical Officer | Sell | 24 | $9.56 | $229 |
| Aug 18, 2025 | Otero Jose ManuelChief Technical Officer | Sell | 721 | $9.27 | $7K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance